Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 10, Issue 2, 2010, Pages 125-132

  Kurth, Florian ^a,b,c   Bélard, Sabine ^a,b,d   Adegnika, Ayola A ^a,b   Gaye, Oumar ^e   Kremsner, Peter G ^a,b   Ramharter, Michael ^a,f  

^a ALBERT SCHWEITZER HOSPITAL   (Gabon)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; ARTESUNATE PLUS PYRONARIDINE; DIHYDROARTEMISININ; MEFLOQUINE; PYRONARIDINE; UNCLASSIFIED DRUG;

CHILDHOOD DISEASE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; MALARIA FALCIPARUM; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TABLET FORMULATION; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ANTI-INFECTIVE AGENTS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; INFANT; MALARIA; PATIENT SELECTION; TABLETS; TREATMENT OUTCOME;

EID: 74849111616     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70327-5     Document Type: Review

References (29)

1. Abdulla S., Sagara I., Borrmann S., et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 372 (2008) 1819-1827
2. Bouyou-Akotet MK, Ramharter M, Ngoungou EB, et al. Efficacy and safety of paediatric artesunate-mefloquine drug formulations for the treatment of uncomplicated falciparum malaria in Gabon. Wien Klin Wochenschr (in press).
3. Thompson R. Treatment of pediatric patients with uncomplicated acute P falciparum malaria with pyronaridine artesunate granules or crushed tablet of artemether/lumefantrine in a phase III controlled trial-satellite symposium: treating malaria with pyronaridine-artesunate. 57th Annual Meeting of the American Society of Tropical Medicine and Hygiene; New Orleans, LA, USA; Dec 7-11, 2008.
4. Chanda P., and Moonga H. Assessment of therapeutic efficacy of antimalarials in children under five years in the sentinel districts of Zambia in 2005 transmission season (2006), Operational Research Office, National Malaria Control Centre, Lusaka
5. Chanthap L., Tsuyuoka R., Na-Bangchang K., et al. Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine. Southeast Asian J Trop Med Public Health 36 (2005) 34-43
6. Denis M.B., Davis T.M., Hewitt S., et al. Efficacy and safety of dihydroartemisinin-piperaquine (artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis 35 (2002) 1469-1476
7. Gaye O., Tine R.C., Faye B., and Ndiaye J.L. A randomized trial of artesunate mefloquine (pediatric artequin) versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children-study report (2009), Cheikh Anta Diop University, Dakar
8. Juma E.A., Obonyo C.O., Akhwale W.S., and Ogutu B.R. A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya. Malar J 7 (2008) 262
9. Karunajeewa H., Lim C., Hung T.Y., et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol 57 (2004) 93-99
10. Kouame K.J., Houenou Y.A., and Kouakou Y.G. Comparative study of artemether suspension monotherapy in 2 different regimes with a combination suspension containing artemether-lumefantrine for the treatment of simple childhood malaria in Abidjan, Ivory Coast-study report (2003), Dafra Pharma, Turnhout
11. Ramharter M., Kurth F., Schreier A.C., et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis 198 (2008) 911-919
12. Ramharter M., Kurth F.M., Belard S., et al. Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. J Antimicrob Chemother 60 (2007) 1091-1096
13. Salah M.T., Faroug M., Magzoub M.M., and Adam I. Efficacy of artemether-lumfantrine (co-artesiane®) suspension in the treatment of uncomplicated Plasmodium falciparum malaria among children under 5 years in eastern Sudan. Trop J Pharm Res 5 (2006) 551-555
14. Kremsner P.G., and Krishna S. Antimalarial combinations. Lancet 364 (2004) 285-294
15. Teklehaimanot A., and Teklehaimanot H.D. Alternative form of artemether-lumefantrine for infants. Lancet 372 (2008) 1786-1787
16. WHO. World Malaria Report 2008 (2008), World Health Organization, Geneva. http://www.who.int/malaria/publications/atoz/9789241563697/en/index.html (accessed Dec 22, 2009).
17. Higgins J.P.T., and Green S. Cochrane handbook for systematic reviews of interventions. In: Higgins J.P.T., and Green S. (Eds). The cochrane library, issue 4 (2006), John Whiley and Sons, Chichester
18. Sirima SB, Tono AB, Gansané A, et al. A randomized trial comparing efficacy and safety of artesunate-amodiaquine given as combined or individual therapies for the treatment of acute, uncomplicated Plasmodium falciparum malaria in children in Burkina Faso. 5th European Congress on Tropical Medicine and International Health; Amsterdam, Netherlands; May 24-28, 2007. Abstract O27-71.
19. Pamba A., and Maitland K. Fluid management of severe falciparum malaria in African children. Trop Doct 34 (2004) 67-70
20. Snow R.W., Korenromp E.L., and Gouws E. Pediatric mortality in Africa: plasmodium falciparum malaria as a cause or risk?. Am J Trop Med Hyg 71 (2004) 16-24
21. Winch P.J., Gilroy K.E., Wolfheim C., et al. Intervention models for the management of children with signs of pneumonia or malaria by community health workers. Health Policy Plan 20 (2005) 199-212
22. Kremsner P.G., Valim C., Missinou M.A., et al. Prognostic value of circulating pigmented cells in African children with malaria. J Infect Dis 199 (2009) 142-150
23. Goodman C.A., and Mills A.J. The evidence base on the cost-effectiveness of malaria control measures in Africa. Health Policy Plan 14 (1999) 301-312
24. Cram A., Breitkreutz J., Desset-Brethes S., Nunn T., and Tuleu C. Challenges of developing palatable oral paediatric formulations. Int J Pharm 365 (2009) 1-3
25. Strickley R.G., Iwata Q., Wu S., and Dahl T.C. Pediatric drugs-a review of commercially available oral formulations. J Pharm Sci 97 (2008) 1731-1774
26. WHO. Guidlines for the treatment of malaria (2006), World Health Organization, Geneva. http://www.who.int/malaria/publications/atoz/9241546948/en/index.html (accessed Dec 22, 2009).
27. White N.J. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41 (1999) 301-308
28. European Parliament and the Council of the European Union. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2006_1 901/reg_2006_1901_en.pdf (accessed Dec 22, 2009).
29. US FDA. Food and Drug Administration Amendments Act of 2007. http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110_cong_publi c_laws&docid=f:publ085.110 (accessed Dec 22, 2009).